Willemina R. Geurts-Giele, PhD, discusses 2 approaches used to detect the MET exon 14 skipping mutation in patients with non-small cell lung cancer.
Willemina R. Geurts-Giele, PhD, University Medical Center, Rotterdam, The Netherlands, discusses 2 approaches used to detect theMETexon 14 skipping mutation in patients with non-small cell lung cancer (NSCLC).
Clinicians can use either RNA or DNA, Geurts-Giele says. With RNA, a simple polymerase chain reaction is used because it is the same event, which is very easy. However, the downside is that patients with NSCLC do not have as much material.
DNA analyses are routinely done in pathology departments, while the use of RNA is still evolving in labs. In her analysis, Guerts-Giele used DNA analysis to determine theMETexon 14 skipping mutation because they regularly run the analysis on their patient’s materials.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More